Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Nuclear receptors take center stage in Th17 cell–mediated autoimmunity
Jennifer J. Heller, Ju Qiu, Liang Zhou
Jennifer J. Heller, Ju Qiu, Liang Zhou
View: Text | PDF
Commentary

Nuclear receptors take center stage in Th17 cell–mediated autoimmunity

  • Text
  • PDF
Abstract

Liver X receptors (LXRs) are nuclear receptors involved in cholesterol homeostasis. Notably, they are also expressed by T cells and are involved in regulating T cell proliferation and differentiation. In this issue of the JCI, Cui et al. have elucidated the molecular mechanism underlying the effects of LXR activation on a subset of T cells known as Th17 cells in mice and humans. Specifically, they showed that LXR-induced Srebp-1 inhibits Il17 transcription by binding to the Il17 promoter through interaction with the aryl hydrocarbon receptor (Ahr), a transcription factor known to enhance Th17 cell responses.

Authors

Jennifer J. Heller, Ju Qiu, Liang Zhou

×

Figure 1

Molecular mechanisms underlying LXR-mediated negative regulation of IL-17 expression in Th17 cells.

Options: View larger image (or click on image) Download as PowerPoint
Molecular mechanisms underlying LXR-mediated negative regulation of IL-1...
(A) In this issue of the JCI, Cui et al. report that Ahr, a ligand-dependent transcription factor, increases IL-17 expression by binding to the Il17 promoter (13). (B) LXR activation by its agonists induces and activates Srebp-1. A putative binding site of Srebp-1 is found at the E-box element on the Il17 promoter that overlaps with the Ahr-binding site, suggesting that Srebp-1 competes with Ahr for binding to this region of the Il17 promoter to suppress the activating effects of Ahr on IL-17 expression. Srebp-1 interacts with the PAS domain of Ahr, subsequently blocking the enhancement of Il17 transcription. LXR activation also inhibits the expression of other genes implicated in Th17 cell differentiation (e.g., Ahr).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts